Work

Supplementary figure S1 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma

Year: 2024

Type: supplementary-materials

Abstract: The study design illustrated here shows the treatment phase with combination paclitaxel and pembrolizumab, followed by maintenance pembrolizumab if disease is stable or improved after 6 months of combination therapy.

DOI: 10.1158/2767-9764.25288985

Authors: Rhonda L. Bitting, Janet A. Tooze, Michael Goodman, Donald C. Vile, Jessica M. Brown, Christopher Y. Thomas, Morgan Neve, Mitra Kooshki, Safoa Addo, Pierre L. Triozzi, Purnima Dubey

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4392156081

Cites:

Cited by:

Related to: 10